Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …

Herein, we present the long-term follow-up of the randomized E1912 trial comparing the
long-term efficacy of ibrutinib–rituximab (IR) therapy to fludarabine, cyclophosphamide, and …

Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …

Background Data regarding the efficacy of treatment with ibrutinib–rituximab, as compared
with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in …

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

Abstract iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus
obinutuzumab (n= 113) versus chlorambucil plus obinutuzumab (n= 116) as first-line …

Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West,
has undergone a revolution in the past few years with the development of agents that target …

Background Both continuous therapy with acalabrutinib and fixed-duration therapy with
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …